Photo Credit: David Levinson
Scientific Frontline: Extended "At a Glance" Summary: Statin-Induced Muscle Myopathy Mechanism
The Core Concept: Researchers at McMaster University have identified the specific immune and metabolic pathway responsible for the muscle pain and weakness frequently caused by statin medications, offering a route to mitigate these side effects without compromising the drugs' cardiovascular benefits.
Key Distinction/Mechanism: While statins effectively lower cholesterol, they simultaneously disrupt cellular energy production within muscle tissue. This metabolic disruption triggers an inflammatory immune response directly within the muscle cells, causing structural damage. Crucially, this immune-metabolic mechanism operates entirely independently from the biochemical pathway that lowers cholesterol.
Major Frameworks/Components:
- Metabolic Disruption: Statins interfere with the standard energy production cycles of muscle cells.
- Autoimmune Inflammatory Response: The altered metabolism within the cell triggers a localized immune response, establishing a direct link between cellular metabolism and intracellular immunity.
- Targeted Immune Blockade: Experimental models in mice and isolated muscle cells demonstrated that suppressing this specific immune response prevents subsequent muscle damage.
Branch of Science: Biochemistry, Biomedical Sciences, Immunology, and Pharmacology.
Future Application: The discovery introduces novel therapeutic targets for drug development, potentially yielding adjunct medications that block the metabolic-immune trigger. This could allow statin-intolerant patients to safely resume, or maintain appropriate dosages of, cholesterol-lowering therapies.
Why It Matters: Statins are highly effective for reducing cardiovascular disease risk, yet an estimated 7% to 29% of patients experience muscle symptoms that lead to dosage reductions or medication abandonment. Separating the vital therapeutic effects from the adverse metabolic effects could significantly improve cardiovascular health outcomes and patient compliance globally.
Millions of people rely on statins—a medication used to lower cholesterol and reduce the risk of heart attack and stroke. But for some, the drugs come with an unwelcome trade-off: muscle pain, weakness, and exercise intolerance that can make it difficult to continue treatment.
Now, researchers at McMaster University have uncovered a biological pathway that may explain why those side effects occur, opening the door to future therapies that could make statins easier to tolerate while maintaining their lifesaving cardiovascular benefits.
Published in Science Advances, the study identifies an immune and metabolic mechanism that drives statin-induced muscle damage, challenging long-standing assumptions about how these side effects develop.
"Statins are among the most effective medications we have for reducing cardiovascular disease risk and preventing early death," said Jonathan Schertzer, professor in McMaster's Department of Biochemistry and Biomedical Sciences and senior author of the study.
"Unfortunately, muscle side effects lead some people to reduce their dose or stop taking the medication altogether. We wanted to understand why this happens and whether it might be possible to separate the side effects from the benefits."
Statin-associated muscle symptoms affect an estimated 7 to 29 percent of people who take the drugs. While researchers have long known that statins can sometimes cause muscle problems, the biological mechanisms behind those effects have remained unclear.
Led by first authors Nazli Robin and Nicole Barra of the Schertzer Lab at McMaster, the team found that statins can disrupt how muscle cells produce energy, triggering an immune response that damages muscle tissue. In experiments using muscle cells and mouse models, researchers were able to prevent much of that damage by blocking the immune response.
"One of the most exciting findings of the research is that the mechanism causing muscle side effects appears to be separate from the mechanism that lowers cholesterol," said Schertzer. "That suggests it may one day be possible to target the side effects without interfering with the cardiovascular benefits that make statins so valuable."
The study also revealed an unexpected link between metabolism and immunity. Researchers found that changes in muscle cell metabolism triggered an immune response within the cells themselves, providing new insight into how inflammation can contribute to drug side effects.
Although additional research will be needed before the findings can be translated into therapies for patients, the discovery identifies several potential targets for future drug development aimed at preventing statin intolerance.
"These findings give us a clearer understanding of why some patients experience muscle symptoms and provide promising directions for making these important medications safer and more effective in the future," added Schertzer.
Additional information: The study reflects a broad international collaboration that included researchers from the Centre International de Recherche en Infectiologie (CIRI) in Lyon, France; the Centre for Muscle Research at the University of Melbourne, Australia; the Murdoch Children's Research Institute and The Royal Children's Hospital in Australia; York University in Canada; and McMaster's Department of Pathology and Molecular Medicine.
Funding: The research was funded by the Natural Sciences and Engineering Research Council of Canada (NSERC).
Published in journal: Science Advances
Authors: Nazli Robin, Nicole G. Barra, Kevin P. Foley, Yujin E. Li, Akhilesh K. Tamrakar, Danish Patoli, Irena A. Rebalka, Tabitha Cree, Kaitlyn Bibby, Khang Nguyen, Rhianna Davis, Darryl Y. Chan, Brittany M. Duggan, Brandyn D. Henriksbo, Megan E. Borges, Dana Kukje Zada, Han Fang, Daniel M. Marko, Paul Gregorevic, Kevin I. Watt, Richard J. Mills, Gary Sweeney, Thomas J. Hawke, Bénédicte F. Py, and Jonathan D. Schertzer
Source/Credit: McMaster University
Edited by: Scientific Frontline
Reference Number: bchm070626_01
.jpg)